Valeo Pharma Inc
TSX:VPH
Balance Sheet
Balance Sheet Decomposition
Valeo Pharma Inc
Current Assets | 25m |
Cash & Short-Term Investments | 9.6m |
Receivables | 5.1m |
Other Current Assets | 10.3m |
Non-Current Assets | 15.3m |
PP&E | 2.6m |
Intangibles | 12.7m |
Current Liabilities | 51.6m |
Accounts Payable | 15.8m |
Short-Term Debt | 26.4m |
Other Current Liabilities | 9.4m |
Non-Current Liabilities | 35.8m |
Long-Term Debt | 35m |
Other Non-Current Liabilities | 777k |
Balance Sheet
Valeo Pharma Inc
Oct-2016 | Oct-2017 | Oct-2018 | Oct-2019 | Oct-2020 | Oct-2021 | Oct-2022 | Oct-2023 | ||
---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||
Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
2
|
23
|
8
|
|
Cash |
0
|
0
|
0
|
0
|
3
|
2
|
23
|
8
|
|
Total Receivables |
3
|
1
|
1
|
1
|
1
|
2
|
5
|
7
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
1
|
5
|
6
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
0
|
0
|
0
|
1
|
1
|
8
|
10
|
10
|
|
Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
1
|
|
Total Current Assets |
3
|
1
|
1
|
2
|
5
|
12
|
41
|
25
|
|
PP&E Net |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
|
PP&E Gross |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Intangible Assets |
1
|
2
|
2
|
4
|
5
|
7
|
15
|
13
|
|
Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Assets |
4
N/A
|
3
-20%
|
3
0%
|
6
+72%
|
11
+89%
|
21
+92%
|
58
+177%
|
41
-29%
|
|
Liabilities | |||||||||
Accounts Payable |
1
|
1
|
2
|
4
|
4
|
10
|
12
|
11
|
|
Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Short-Term Debt |
0
|
1
|
1
|
0
|
0
|
0
|
1
|
3
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
5
|
0
|
2
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
4
|
|
Total Current Liabilities |
1
|
2
|
3
|
4
|
4
|
15
|
15
|
20
|
|
Long-Term Debt |
2
|
3
|
1
|
1
|
3
|
3
|
61
|
60
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
Total Liabilities |
3
N/A
|
6
+82%
|
5
-21%
|
6
+23%
|
8
+35%
|
19
+140%
|
76
+301%
|
82
+7%
|
|
Equity | |||||||||
Common Stock |
0
|
0
|
5
|
9
|
15
|
25
|
26
|
32
|
|
Retained Earnings |
1
|
3
|
6
|
9
|
13
|
25
|
52
|
79
|
|
Additional Paid In Capital |
0
|
0
|
0
|
1
|
2
|
3
|
4
|
5
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
|
Total Equity |
1
N/A
|
3
N/A
|
1
+47%
|
0
+98%
|
3
N/A
|
2
-33%
|
18
N/A
|
40
-126%
|
|
Total Liabilities & Equity |
4
N/A
|
3
-20%
|
3
0%
|
6
+72%
|
11
+89%
|
21
+92%
|
58
+177%
|
41
-29%
|
|
Shares Outstanding | |||||||||
Common Shares Outstanding |
31
|
31
|
45
|
50
|
64
|
79
|
82
|
99
|